Intensive Care Medicine

, Volume 24, Issue 7, pp 663–672 | Cite as

Antithrombin III in patients with severe sepsis

A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis
  • B. Eisele
  • H. Heinrichs
  • U. Delvos
  • M. Lamy
  • L. G. Thijs
  • H. O. Keinecke
  • H. P. Schuster
  • F. R. Matthias
  • F. Fourrier
Original

Abstract

Objectives: To evaluate the safety and potential efficacy of antithrombin III (AT III) in reducing mortality in patients with severe sepsis.

Design: Prospective, randomized, placebo-controlled, double-blind, phase II, multicenter, multinational clinical trial.

Setting: Seven academic medical center intensive care units (ICU) in Belgium, Denmark, the Netherlands, Norway and Sweden.

Patients: 42 patients with severe sepsis who received standard supportive care and antimicrobial therapy, in addition to the administration of AT III or placebo.

Interventions: Patients received either an intravenous loading dose of 3000IU AT III followed by a maintenance dose of 1500 IU every 12 h for 5 days or equivalent amounts of placebo.

Measurements and results: All patients were evaluated for safety and for 30-day all-cause mortality.

Conclusions: The administration of AT III was safe and well-tolerated. It was followed by a 39 % reduction in 30-day all-cause mortality (NS). The reduction in mortality was accompanied by a considerably shorter stay in the ICU. Patients treated with AT III exhibited a better performance in overall severity of illness and organ failure scores (Acute Physiology and Chronic Health Evaluation II, multiple organ failure, organ system failure), which was noticeable soon after initiation of treatment. Patients treated with AT III demonstrated a better resolution of pre-existing organ failures and a lower incidence of new organ failures during the observation period. A meta-analysis comprising this and two other double-blind, placebo-controlled trials with AT III with a total of 122 patients suffering from severe sepsis confirms the positive trend. The results of the meta-analysis demonstrate a 22.9 % reduction in 30-day all-cause mortality in patients treated with AT III. Although still too small to be confirmative, the meta-analysis clearly points to the fact that a sufficiently powered phase III trial is warranted to prove whether AT III has a beneficial role in the treatment of severe sepsis.

Key words

Antithrombin III Sepsis Multiorgan failure Clinical trial Meta-analysis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bone RC, Balk RA, Cerra FB (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 101: 1644–1655PubMedCrossRefGoogle Scholar
  2. 2.
    Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA (1989) Sepsis syndrome: a valid clinical entity. Crit Care Med 17: 389–393PubMedCrossRefGoogle Scholar
  3. 3.
    Fisher CJ, Dhainaut JFA, Opal SM, Pribble JP, Balk RA, Slotman GJ, Ibertie TJ, Rackow EC, Shapiro MJ, Greenman RL, Reines HD, Shelly MP, Thompson BW, LaBrecque JF, Catalano MA, Knaus WA, Sadoff JC (1994) Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome. JAMA 271: 1836–1843PubMedCrossRefGoogle Scholar
  4. 4.
    Greenman RL, Schein RMH, Martin MA, Wenzel RP, Maclntytre NR, Emmanuel G, Chmel H, Kohler RB, McCarthy M, Plouffe J, Russell RN (1991) A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA 266:1097–1102PubMedCrossRefGoogle Scholar
  5. 5.
    Ziegler EJ, Fisher CJ, Sprung CL, Straube RC, Sadoff JC, Foulke GE, Wortel CH, Fink MP, Dellinger P, Teng NNH, Allen IE, Berger HJ, Knatterud GL, LoBuglio AF, Smith CR (1991) Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo controlled trial. N Engl J Med 324:429–436, 486–487PubMedCrossRefGoogle Scholar
  6. 6.
    Dinarello CA, Gelfand JA, Wolff SM (1993) Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA 269: 1829–1835PubMedCrossRefGoogle Scholar
  7. 7.
    Dhainaut F-J A, Tenaillon A, Le Tulzo Y, Schlemmer B, Solet J-P, Wolff M, Holzapfel L, Zeni F, Dreyfuss D, Mira J-P, De Vathaire F, Guinot P (1994) Platelet-activating factor receptor antagonist BN52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. Crit Care Med 22: 1720–1728PubMedCrossRefGoogle Scholar
  8. 8.
    McCloskey RV, Straube RC, Sanders C, Smith SM, Smith CR (1994) Treatment of septic shock with human monoclonal antibody HA-1 A. Ann Intern Med 121: 1–5PubMedCrossRefGoogle Scholar
  9. 9.
    Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, Bone R, Wenzel RP, Balk R, Allred R, Pennington JE, Wherry JC (1995) Efficacy and safety of monoclonal antibody to human tumor necrosis factor a in patients with sepsis syndrome. JAMA 273: 934–941PubMedCrossRefGoogle Scholar
  10. 10.
    Piguet PF, Grau GE, Vassalli P (1990) Subcutaneous perfusion of tumor necrosis factor induces local proliferation of fibroblasts, capillaries, and epidermal cells, or massive tissue necrosis. Am J Pathol 136:103–110PubMedCentralPubMedGoogle Scholar
  11. 11.
    Remick DG, Kunkel RG, Larric JW, Kunkel SL (1987) Acute in vivo effects of human recombinant tumor necrosis factor. Lab Invest 56: 583–590PubMedGoogle Scholar
  12. 12.
    van Deventer SJH, Buller HR, ten Cate JW, Aarden LA, Hack CE, Sturk A (1990) Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic and complement pathways. Blood 76: 2520–2526PubMedGoogle Scholar
  13. 13.
    Bauer KA, ten Cate H, Barzegar S, Spriggs DR, Sherman ML, Rosenberg RD (1989) Tumor necrosis factor infusions have a procoagulant effect on the hemostatic mechanism of humans. Blood 74:165–172PubMedGoogle Scholar
  14. 14.
    van der Poll T, Buller HR, ten Cate H (1990) Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 322: 1622–1627PubMedCrossRefGoogle Scholar
  15. 15.
    Fourrier F, Chopin C, Goudemand J, Hendrycx S, Caron C, Rime A, Marey A, Lestavei P (1992) Septic shock, multiple organ failure, and disseminated intravascular coagulation. Chest 101: 816–823PubMedCrossRefGoogle Scholar
  16. 16.
    Dickneite G, Pâques EP (1993) Reduction of mortality with antithrombin III in septicemic rats: a study of Klebsiella pneumoniae induced sepsis. Thromb Haemost 2: 98–102Google Scholar
  17. 17.
    Rao LVM, Nordfang O, Hoang AD, Pendurthi UR (1995) Mechanism of antithrombin III inhibition of factor Vila/tissue factor activity on cell surfaces. Comparison with tissue factor pathway inhibitor/factor Xa-induced inhibition of factor Vila/tissue factor activity. Blood 85:121–129PubMedGoogle Scholar
  18. 18.
    Smith-Erichsen N, Aasen AO, Gallimore MJ, Amundsen E (1982) Studies of components of the coagulation systems in normal individuals and septic shock patients. Circ Shock 9: 491–197PubMedGoogle Scholar
  19. 19.
    Voss R, Matthias FR, Borkowski G, Reitz D (1990) Activation and inhibition of fibrinolysis in septic patients in an internal intensive care unit. Br J Haematol 75: 99–105PubMedCrossRefGoogle Scholar
  20. 20.
    Havemann K, Gramse M (1984) Physiology and pathophysiology of neutral proteinases of human granulocytes. In: Hörl WH, Heidland A (eds) Proteases: potential role in health and disease. Plenum, New York, pp 1–20CrossRefGoogle Scholar
  21. 21.
    Seitz R, Wolf M, Egbring R, Havemann K (1989) The disturbance of haemostasis in septic shock: role of neutrophil elastase and thrombin, effects of antithrombin III and plasma. Eur J Haematol 43: 22–28PubMedCrossRefGoogle Scholar
  22. 22.
    Schipper HG, Jenkins CSP, Kahl LH, Ten Cate JW (1978) Antithrombin III transfusion in disseminated intravascular coagulation. Lancet I: 854–856CrossRefGoogle Scholar
  23. 23.
    Fourrier F, Chopin C, Huart J, Runge I, Caron C, Goudemand J (1993) Doubleblind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 104: 882–888PubMedCrossRefGoogle Scholar
  24. 24.
    Schuster HP, Matthias FR (1995) Antithrombin III in severe sepsis. 15th International Symposium of Intensive Care and Emergency Medicine, Brussels, March, 21–24, 1995Google Scholar
  25. 25.
    Knaus WA, Draper EA, Wagner DP, Zimmermann JE (1985) APACHE II: a severity of disease classification system. Crit Care Med 13: 818–829PubMedCrossRefGoogle Scholar
  26. 26.
    Goris RJA, te Boekhorst TPA, Nuytinck JKS, Gimbrère JSF (1985) Multiple-organ-failure. Generalized autodestructive inflammation? Arch Surg 120: 1109–1115PubMedCrossRefGoogle Scholar
  27. 27.
    Knaus WA, Draper EA, Wagner DP, Zimmermann JE (1985) Prognosis in acute organ system failure (OSF). Ann Surg 202: 685–693PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Jordan DA, Miller CF, Kubos KL, Rogers MC (1987) Evaluation of sepsis in a critically III surgical population. Crit Care Med 15: 897–904PubMedCrossRefGoogle Scholar
  29. 29.
    Kleinbaum DG, Kupper LL, Morgenstern H (1982) Epidemiologie research: principles and quantitative methods. Wadsworth, Belmont, CAGoogle Scholar
  30. 30.
    Galbraith RJ (1988) A note on graphical presentations of estimated odds ratios from several clinical trials. Stat Med 7: 889–894PubMedCrossRefGoogle Scholar
  31. 31.
    Williams J, Maier RV (1992) The inflammatory response. J Intensive Care Med 7: 53–66Google Scholar
  32. 32.
    Regoeczi E, Brain MC (1969) Organ distribution of fibrin in disseminated intravascular coagulation. Br J Haematol 17:73–79PubMedCrossRefGoogle Scholar
  33. 33.
    Robboy SJ, Colman RW, Minna JD (1972) Pathology of disseminated intravascular coagulation (DIC): analysis of twenty-six cases. Hum Pathol 3: 327PubMedCrossRefGoogle Scholar
  34. 34.
    Taylor FB, Emerson TE, Jordan R, Chang AK, Blick KE (1988) Antithrombin III prevents the lethal effects of Escherichia coli infusion in baboons. Circ Shock 26: 227–235PubMedGoogle Scholar
  35. 35.
    Taylor FB, Chang ACK, Peer GT, Mather T, Blick K, Catlett R, Lockhart MS, Esmon CT (1991) DEGR-factor Xa blocks disseminated intravascular coagulation initiated by Escherichia coli without preventing shock or organ damage. Blood 78: 364–368PubMedGoogle Scholar
  36. 36.
    Yamauchi T, Umeda F, Inoguchi T, Nawata H (1989) Antithrombin III stimulates prostacyclin production by cultured aortic endothelial cells. Bio-chem Biophys Res Commun 163: 1404–1411CrossRefGoogle Scholar
  37. 37.
    Horie S, Ishii H, Kazama M (1990) Heparin-like glycosaminoglycan is a receptor for antithrombin III — dependent but not for thrombin-dependent prostacyclin production in human endothelial cells. Thromb Res 59: 895–904PubMedCrossRefGoogle Scholar
  38. 38.
    Okajima K, Uchiba M, Murakami K (1995) Antithrombin replacement in DIC and MOE In: Vincent JL (ed) Yearbook of intensive care and emergency medicine. Springer, Berlin Heidelberg New York, pp 457–464CrossRefGoogle Scholar
  39. 39.
    Blauhut B, Kramar H, Vinazzer H, Bergmann H (1985) Substitution of antithrombin III in shock and DIC: a randomized study. Thromb Res 39: 81–89PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1998

Authors and Affiliations

  • B. Eisele
    • 1
  • H. Heinrichs
    • 1
  • U. Delvos
    • 1
  • M. Lamy
    • 2
  • L. G. Thijs
    • 3
  • H. O. Keinecke
    • 4
  • H. P. Schuster
    • 5
  • F. R. Matthias
    • 6
  • F. Fourrier
    • 7
  1. 1.Clinical Research DepartmentCenteon Pharma GmbHMarburgGermany
  2. 2.Centre Hospitalier Universitaire de LiègeLiègeBelgium
  3. 3.Medical Intensive Care UnitFree University of AmsterdamAmsterdamThe Netherlands
  4. 4.Biometrics DepartmentCenteon Pharma GmbHMarburgGermany
  5. 5.Municipal HospitalHildesheimGermany
  6. 6.Medical CentreUniversity of GiessenGermany
  7. 7.Service de Réanimation PolyvalenteHôpital B, CHRULilleFrance
  8. 8.Clinical DevelopmentSolvay PharmaceuticalsHannoverGermany

Personalised recommendations